Burden of digestive diseases in the United States Part III: Liver ,
, , p.391
, Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic 392 cholangiocarcinoma: preliminary results, J Cancer Res Clin Oncol, vol.143, issue.3, pp.481-393, 2017.
Prognostic 395 Factors in Overall Survival of Patients with Unresectable Intrahepatic 396 ,
, Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in 397 Therapy-Naïve Patients, vol.41, 2018.
Radioembolization for Unresectable 400 ,
, Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in 401
, Solid Tumors 1.1 Imaging Response and Survival, Cancer Biother Radiopharm, vol.402, issue.5, pp.161-168, 2017.
Is there a role for Ytrrium-90 in the treatment of 404 unresectable and metastatic intrahepatic cholangiocarcinoma?, Am J Surg, vol.215, issue.3, pp.467-470, 2018. ,
, , p.407
, Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single 408
, Institution Retrospective Study, J Vasc Interv Radiol JVIR, vol.29, issue.8, 2018.
Yttrium-90 glass microspheres radioembolization 411 (RE) for biliary tract cancer: a large single-center experience, Eur J Nucl Med Mol, p.412 ,
, Imaging, vol.46, issue.3, pp.669-676, 2019.
Research reporting standards for 414 radioembolization of hepatic malignancies, J Vasc Interv Radiol JVIR, vol.22, issue.3, pp.265-415, 2011. ,
Boosted selective internal radiation therapy with 417 ,
, 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new 418 personalized promising concept, Eur J Nucl Med Mol Imaging, vol.40, issue.7, pp.1057-1068, 2013.
Treatment of 430 unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a 431 systematic review and pooled analysis, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc, vol.432 ,
, Surg Oncol, vol.41, issue.1, pp.120-127, 2015.
Improving patient selection for selective 434 internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study ,
Phase II study of first-line radioembolization with 437 yttrium-90 glass microspheres for intrahepatic cholangiocarcinoma, Liver Int Off J Int Assoc Study Liver, vol.37, issue.7, pp.482-482, 2017. ,
Guidelines for the diagnosis and management 440 of intrahepatic cholangiocarcinoma, J Hepatol, vol.60, issue.6, 2014. ,
Biliary cancer: 443 ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, p.444 ,
, Off J Eur Soc Med Oncol, vol.27, issue.5, pp.28-37, 2016.
Selective internal radiotherapy (SIRT) versus 446 transarterial chemoembolization (TACE) for the treatment of intrahepatic 447 cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial ,
, Trials, vol.15, p.311, 2014.
The Post-SIR-Spheres Surgery Study, vol.4 ,
, Retrospective Analysis of Safety Following Hepatic Resection or Transplantation, p.451
, Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90
, Ann Surg Oncol, vol.24, issue.9, pp.2465-2473, 2017.
Intra-arterial yttrium-90 radioembolization 455 combined with systemic chemotherapy is a promising method for downstaging 456 unresectable huge intrahepatic cholangiocarcinoma to surgical treatment, Ann Surg, p.457 ,
, Oncol, vol.22, issue.9, pp.3102-3108, 2015.
Neoadjuvant chemotherapy for initially unresectable 459 intrahepatic cholangiocarcinoma, Br J Surg, vol.105, issue.7, pp.839-847, 2018. ,
Intra-arterial Therapy for Advanced Intrahepatic 472 Cholangiocarcinoma: A Multi-institutional Analysis, Ann Surg Oncol, vol.473, issue.12, pp.3779-3786, 2013. ,
, Institutional Phase II Study of High-Dose, vol.475
, Hypofractionated Proton Beam Therapy in Patients With Localized, p.476
, J Clin Oncol Off J Am, vol.477
, Soc Clin Oncol, vol.34, issue.5, pp.460-468, 2016.
Survival Data for Advanced Intrahepatic Cholangiocarcinoma from the 479 ABC-01, -02 And -03 Clinical Studies, ILCA Meet, p.14, 2018. ,
Personalized dosimetry with intensification using 481 ,
, 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in 482 hepatocellular carcinoma patients with portal vein thrombosis, J Nucl Med Off Publ Soc, vol.483
, Nucl Med, vol.56, issue.3, pp.339-346, 2015.
High impact of macroaggregated albumin-based 485 tumour dose on response and overall survival in hepatocellular carcinoma patients 486 treated with (90) Y-loaded glass microsphere radioembolization, Liver Int Off J Int, vol.487 ,
, Assoc Study Liver, vol.37, issue.1, pp.101-110, 2017.